医学
临床试验
耐火材料(行星科学)
多发性骨髓瘤
尴尬
肿瘤科
双特异性抗体
内科学
抗体
免疫学
心理学
单克隆抗体
社会心理学
物理
天体生物学
作者
Ross S. Firestone,Alexander M. Lesokhin,Saad Z. Usmani
出处
期刊:Blood cancer discovery
[American Association for Cancer Research]
日期:2023-10-12
卷期号:4 (6): 433-436
被引量:4
标识
DOI:10.1158/2643-3230.bcd-23-0176
摘要
In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens.
科研通智能强力驱动
Strongly Powered by AbleSci AI